| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 410.88 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), was recently introduced in several countries, including Portugal (reimbursement in 2021), as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating proto-oncogene epidermal growth factor receptor mutations (EGFRm), after showing significant efficacy and safety when used in patients with EGFR-T790M resistance mutations. However, despite advances in personalized target treatments in this field, challenges regarding patients’ journey (e.g., therapy selection criteria, EGFR-TKI optimal sequencing, treatment beyond second-line) still exist.
Descrição
Palavras-chave
Lung cancer Non-small-cell lung cancer EGFR mutation Real-world data Tyrosine kinase inhibitors
Contexto Educativo
Citação
Barreto I, Figueiredo S, Tonin FS, Vilariça AS, Hasmucrai D, Alves P. Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer. Port J Card Thorac Vasc Surg. 2023;30(3):9-11.
Editora
Sociedade Portuguesa de Cirurgia Cárdio-Torácica e Vascular